Comparison of monteleukast and rupatadine combination with rupatadine alone for reducing the complications of dengue

INTERVENTION: Intervention1: Rupatadine and Montelukast combination: Rupatadine 10 mg and Montelukast 10 mg combination given orally daily for 5 days. Control Intervention1: Rupatadine: Rupatadine 40 mg given orally daily for 5 days. CONDITION: Health Condition 1: A91‐ Dengue hemorrhagic fever PRIMARY OUTCOME: Proportion of patients with acute dengue infection developing dengue haemorrhagic fever after being treated by intervention drug for 5 days.Timepoint: At 5 days. SECONDARY OUTCOME: Duration of the illness.Timepoint: Observed within 3o days follow‐up period. The proportion of patients that develop liver failure and shock.Timepoint: At 5 days. The proportion of patients that need the use of colloids and blood transfusions.Timepoint: At 5 days. INCLUSION CRITERIA: All patients aged between 18 and 60 years with confirmed dengue infection by a positive dengue NS1 test or positive PCR for acute dengue virus infection with a febrile illness of less than or equal to 3 days duration and who will give written informed consent and who do not show any evidence of vascular leak will be recruited.